Related Experiment Videos
Anoxia/reoxygenation-induced leukocyte-endothelial cell interactions
Satoshi Kokura1, Norimasa Yoshida, Toshikazu Yoshikawa
1First Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. s-kokura@mpd.biglobe.ne.jp
Free Radical Biology & Medicine
|August 6, 2002
Summary
Oxidants trigger inflammation by activating NFkappaB, a key transcription factor. Reoxygenation-induced redox imbalance contributes to this process, impacting leukocyte-endothelial cell interactions and adhesion molecule expression.
Area of Science:
- Cellular and Molecular Biology
- Inflammation Research
- Oxidative Stress Biology
Background:
- Oxidants are increasingly recognized for their role in cell responses and gene expression during inflammation.
- Oxidant-induced activation of nuclear factor kappa B (NFkappaB) upregulates inflammatory genes, including endothelial cell adhesion glycoproteins.
- Oxidant effects on cellular regulation may stem from a loss of cellular oxidation-reduction (redox) balance.
Purpose of the Study:
- To review current understanding of leukocyte-endothelial cell interactions.
- To emphasize molecular determinants of inflammation in this context.
- To explore the contribution of reoxygenation-induced redox imbalance to NFkappaB activation and adhesion molecule expression.
Main Methods:
- In vitro studies using endothelial cell monolayers.
- Exposure of cells to anoxia/reoxygenation.
- Analysis of molecular mechanisms underlying inflammatory responses.
Main Results:
- Oxidant-induced activation of NFkappaB is implicated in inflammatory gene upregulation.
- Loss of cellular redox balance is a potential mediator of oxidant effects.
- Reoxygenation contributes to redox imbalance, NFkappaB activation, and adhesion molecule expression.
Conclusions:
- Leukocyte-endothelial cell interactions during inflammation are influenced by oxidants.
- Cellular redox imbalance plays a critical role in mediating inflammatory signaling pathways.
- Understanding these molecular events is crucial for addressing inflammatory pathophysiologies.